XJPX4882
Market cap42mUSD
Jan 21, Last price
561.00JPY
1D
-3.44%
1Q
-7.43%
IPO
-31.00%
Name
Perseus Proteomics Inc
Chart & Performance
P/E
—
P/S
65.71
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
100m
+6.58%
Net income
-1.10b
L+40.34%
CFO
-834m
L+47.78%
Profile
Perseus Proteomics Inc., a drug discovery biotech venture company, develops antibody drugs against cancer and other diseases in Japan. The company is involved in the antibody discovery activities; and antibody research support activities comprising hybridoma antibody sequencing, antibody protein production, and contract antibody research activities, as well as supply of antibody products. Its product pipeline includes PPMX-T001, an anti-hepatocarcinoma antibody; PPMX-T002, an anticancer drug; PPMX-T003, a drug for the treatment of adult T-cell; and PPMX-T004, an antibody drug conjugate. The company was incorporated in 2001 and is headquartered in Tokyo, Japan.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | |
| Income | |||||
Revenues | 100,402 6.58% | 94,201 30.96% | 71,932 5.86% | ||
Cost of revenue | 628,717 | 501,668 | 312,184 | ||
Unusual Expense (Income) | |||||
NOPBT | (528,315) | (407,467) | (240,252) | ||
NOPBT Margin | |||||
Operating Taxes | 1,927 | 1,927 | 1,927 | ||
Tax Rate | |||||
NOPAT | (530,242) | (409,394) | (242,179) | ||
Net income | (1,104,460) 40.34% | (786,999) 31.38% | (599,023) 44.97% | ||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 63,378 | (20) | 2,652,415 | ||
BB yield | -1.60% | 0.00% | -57.98% | ||
| Debt | |||||
Debt current | |||||
Long-term debt | |||||
Deferred revenue | |||||
Other long-term liabilities | 166,487 | 58,988 | 1,000 | ||
Net debt | (1,583,419) | (2,495,934) | (3,223,852) | ||
| Cash flow | |||||
Cash from operating activities | (833,898) | (564,274) | (476,842) | ||
CAPEX | (158,971) | (170,548) | (33,868) | ||
Cash from investing activities | (150,343) | (212,989) | (33,868) | ||
Cash from financing activities | 63,943 | (20) | 2,647,548 | ||
FCF | (530,242) | (409,394) | (237,490) | ||
| Balance | |||||
Cash | 1,541,419 | 2,444,934 | 3,214,852 | ||
Long term investments | 42,000 | 51,000 | 9,000 | ||
Excess cash | 1,578,399 | 2,491,224 | 3,220,255 | ||
Stockholders' equity | (932,681) | 171,012 | 927,012 | ||
Invested Capital | 2,497,513 | 2,271,790 | 2,205,471 | ||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 11,788 | 11,759 | 10,997 | ||
Price | 336.00 12.75% | 298.00 -28.37% | 416.00 | ||
Market cap | 3,960,826 13.03% | 3,504,292 -23.40% | 4,574,615 | ||
EV | 2,377,407 | 1,008,358 | 1,350,763 | ||
EBITDA | (524,818) | (401,757) | (237,297) | ||
EV/EBITDA | |||||
Interest | 5,528 | ||||
Interest/NOPBT | |||||